Johnson & Johnson to pay $1 Billion Settlement on Risperdal Marketing ProbePosted by in Medical Malpractice
Bloomberg and other sources are reporting that Johnson & Johnson has agreed to pay the U.S. $1 billion to settle the U.S. Attorney’s marketing probe. Read the full report here. Criminal please still may come in this case.
Risperdal was once J&J’s biggest selling drug. It was an anti-psychotic drug approved for use in psychotic disorders, such as schizophrenia. J&J began marketing it for off-label uses, such as bipolar disorder, dementia, mood and anxiety disorders and other unapproved uses.
You can follow any responses to this entry through the RSS 2.0 You can skip to the end and leave a response. Pinging is currently not allowed.